The therapeutic potential for JAK inhibitors for immune-related adverse events from checkpoint inhibitors: a review of the literature
Authors' conclusion
JAK inhibitors are emerging as a promising option for the treatment of immune checkpoint inhibitor-related toxicities.
Study context
- Population
- Patients treated with JAK inhibitors for checkpoint inhibitor-induced immune adverse events (immune-related adverse events (irAEs))case reports, case series, cohort data
- Participants
- 104 patients
- Outcome
- Use of JAKi for irAEs from ICI
Methodological detailsliterature review, Pubmed, EMBASE and MEDLINE searched from inception until 25 May 2025
- Literature review
- Pubmed, EMBASE and MEDLINE searched from inception until 25 May 2025
Pooled result
As reported in the abstract
- Received tofacitinib
- 82%
- Cancer: lung
- 20%
- Cancer: gastric
- 17%
- Cancer: metastatic melanoma
- 16%
- Indication: myocarditis
- 70%
- Indication: myositis
- 33%
- Indication: hepatitis
- 24%
- Tumour progression
- 38%
- Remaining in remission
- 14%
- Died due to cancer progression
- 4%
Original publication
The therapeutic potential for JAK inhibitors for immune-related adverse events from checkpoint inhibitors: a review of the literature. Rheumatology (Oxford). Published 30 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →